Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx Withdraws IPO

NEW YORK (GenomeWeb) – Citing unattractive terms, molecular diagnostics firm AltheaDx has withdrawn its planned initial public offering. 

The San Diego-based firm said in a document filed with the US Securities and Exchange Commission on Monday that it chose not to pursue its IPO at this time as the "terms currently obtainable in the public marketplace are not sufficiently attractive to [the company] to warrant proceeding with the public offering." 

AltheaDx filed a prospectus to go public in December to raise up to $69 million. The following month it raised its target to $74.3 million

The company offers a portfolio of tests for use by clinicians to tailor treatments, such as cardiovascular disease, neuropsychiatric disorders, and pain. AltheaDx acquired the tests when it bought IDgenetix in May 2013.

The tests analyze genes involved in the metabolism and pharmacological activity of drugs and provide clinicians information about the functionality of metabolic enzymes and biological drug targets for each patient, the company said in its prospectus. AltheaDx added that its algorithm screens for unfavorable metabolic interactions that result from multiple prescription drugs, over-the-counter drugs, and herbal supplements, as well as environmental and dietary factors that may change the metabolism of certain drugs. 

Additionally, AltheaDx offers R&D services, primarily in the cancer space, to biopharmaceutical partners, using its expertise in next-generation sequencing, computational biology, and information technology to analyze patient samples from preclinical through clinical development. 

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.